57 163

Cited 0 times in

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

Authors
 Jaehyun Bae  ;  Taegyun Park  ;  Hyeyoung Kim  ;  Minyoung Lee  ;  Bong-Soo Cha 
Citation
 DIABETES & METABOLISM JOURNAL, Vol.45(3) : 326-336, 2021-05 
Journal Title
DIABETES & METABOLISM JOURNAL
ISSN
 2233-6079 
Issue Date
2021-05
MeSH
Diabetes Mellitus, Type 2* / drug therapy ; Humans ; Hypoglycemic Agents / adverse effects ; Pyrimidines ; Thiazolidinediones* / adverse effects
Keywords
Diabetes mellitus , type 2 ; Lobeglitazone ; Thiazolidinediones
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity by activating peroxisome proliferator-activated receptor γ. Rosiglitazone and pioglitazone have been used widely for T2DM treatment due to their potent glycemic efficacy and low risk of hypoglycemia. However, their use has decreased because of side effects and safety issues, such as cardiovascular concerns and bladder cancer. Lobeglitazone (Chong Kun Dang Pharmaceutical Corporation), a novel TZD, was developed to meet the demands for an effective and safe TZD. Lobeglitazone shows similar glycemic efficacy to pioglitazone, with a lower effective dose, and favorable safety results. It also showed pleiotropic effects in preclinical and clinical studies. In this article, we summarize the pharmacologic, pharmacokinetic, and clinical characteristics of lobeglitazone.
Files in This Item:
T202104716.pdf Download
DOI
10.4093/dmj.2020.0272
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Minyoung(이민영) ORCID logo https://orcid.org/0000-0002-9333-7512
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/186832
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links